A Novel Small Molecule Inhibitor of Hepatitis C Virus Entry
Carl J. Baldick(Bristol-Myers Squibb (United States)), Daniel J. Tenney(Bristol-Myers Squibb (Germany)), Ann W. Walsh(Bristol-Myers Squibb (United States)), Michael A. Poss(Princeton University), Nicholas A. Meanwell(Bristol-Myers Squibb (Germany)), Guangzhi Zhai(Bristol-Myers Squibb (United States)), Samuel W. Gerritz(College of Wooster), Mark I. Cockett(Bristol-Myers Squibb (United States)), Charles E. Mazzucco(Bristol-Myers Squibb (United States)), Ronald E. Rose(Bristol-Myers Squibb (United States)), Betsy J. Eggers(Bristol-Myers Squibb (United States)), Mayla Hsu(Bristol-Myers Squibb (United States)), Weixu Zhai(Bristol-Myers Squibb (United States)), Kevin A. Pokornowski(Bristol-Myers Squibb (United States)), Michael Wichroski(Bristol-Myers Squibb (Germany)), Jie Fang(Sun Yat-sen University), Annapurna Pendri(Bristol-Myers Squibb (United States))
Cited by 82
Related Papers
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
|Hepatology|2009|815
Decarboxylative alkylation for site-selective bioconjugation of native proteins via oxidation potentials
|Nature Chemistry|2017|378
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
|Antimicrobial Agents and Chemotherapy|2006|239
Applications of fluorine-containing amino acids for drug design
|European Journal of Medicinal Chemistry|2019|238